Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit
May 14, 2024 07:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
May 07, 2024 07:00 ET
|
ZENTALIS PHARMACEUTICALS
Azenosertib clinical development plan on track with multiple data readouts in gynecological and other cancer types anticipated in the second half of 2024 and into 2025 Final results from Phase 1...
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2024 17:30 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
April 02, 2024 16:05 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 01, 2024 17:30 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 01, 2024 18:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK & SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
February 28, 2024 07:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
February 27, 2024 07:00 ET
|
ZENTALIS PHARMACEUTICALS
Robust azenosertib clinical development plan ongoing and on track with multiple clinical catalysts anticipated, including monotherapy and combination data readouts in gynecological and other cancer...
Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference
February 13, 2024 07:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2024 17:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...